Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care) (COLMYONEU)

October 5, 2023 updated by: University Hospital, Bordeaux

Constitution of a Collection of Residues of Neuromuscular Biopsies From Patients Taken as Part of Their Health Care at the Bordeaux University Hospital for Neuromuscular Disease and Use for Research Projects

Neuromuscular diseases are rare diseases for which significant progress has been made in the context of diagnosis thanks to advances in molecular techniques, but the intimate mechanisms of lesion formation remain poorly understood. Advances in cellular and molecular biology, the development of a few animal models, such as transgenic mice, which make it possible to mimic human pathology have made it possible to better understand the physiopathology of these diseases. However, they still do so very imperfectly and incompletely, making it even more necessary than ever to study diseased human muscle tissue to find new avenues of research or to confirm results obtained by experimentation.

The purpose of this collection of tissue samples for neuro-muscular purposes is to collect such samples under the best conditions in order to promote basic and translational research on muscle diseases.

This is why the CHU de Bordeaux wishes to keep the remainders of samples taken as part of the treatment to constitute a collection of biological samples and associated data kept according to quality standards and in compliance with the regulations in force.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The "COLMYONEU" project is a project to collect leftover frozen neuromuscular biopsy samples from patients taken as part of their health care at the Bordeaux University Hospital for neuromuscular disease.

Its main objective is to store, under the conditions of the CRB standard, residual biological samples from patients with neuromuscular symptoms.

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients with neuromuscular symptoms.

Description

Inclusion criteria

  • Patients treated at Bordeaux University Hospital (neurology services, neuropediatrics), rheumatology, medical genetics for suspected neuromuscular disease.
  • Men and women are affected, adults and minors.

Exclusion criteria

- no exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Constitution of biocollection
Collection of remains of neuromuscular biopsy samples (nerve and muscles)
Other: Residual neuromuscular biopsy
recovery of residual neuromuscular biopsy (nerve ans muscle)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Constitution of a biocollection
Time Frame: 30 years
Collection of leftover frozen neuromuscular biopsy samples from patients taken as part of their health care at the Bordeaux University Hospital for neuromuscular disease.
30 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Bordeaux

Investigators

  • Principal Investigator: Marie Laure NEGRIER, Pr, Université Hospital, Bordeaux

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 26, 2023

Primary Completion (Estimated)

June 25, 2053

Study Completion (Estimated)

June 25, 2053

Study Registration Dates

First Submitted

August 17, 2023

First Submitted That Met QC Criteria

October 5, 2023

First Posted (Estimated)

October 10, 2023

Study Record Updates

Last Update Posted (Estimated)

October 10, 2023

Last Update Submitted That Met QC Criteria

October 5, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2023/26

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuromuscular Diseases

Clinical Trials on Residual neuromuscular biopsy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe